MM-151 is a humanized IgG1 monoclonal antibody targeting EGFR. It binds to multiple regions of the EGFR extracellular domain (ECD) and decreases mutations in circulating free tumor DNA associated with EGFR resistance. MM-151 significantly inhibits EGFR signaling and cell growth and is applicable in research on resistant cancers such as colorectal cancer, non-small cell lung cancer, and triple-negative breast cancer.